Eterna Therapeutics
A life science company researching mRNA cell engineering to create new medicines.
Eterna has in-licensed a portfolio of over 130 patents covering key mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system from Factor Bioscience.
Latest Eterna Therapeutics News & Features
21 December 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze